A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens. After written informed consent is obtained, patients will receive one of the following two treatment regimens: 1) intravenous administration of azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous administration of levofloxacin followed by levofloxacin tablets. At least four study visits are normally conducted up to approximately one month after starting therapy. The objective of this study is to compare the safety and efficacy of the two treatment regimens.

Condition	Treatment or Intervention	Phase
Pneumonia	Drug: IV azithromycin  Drug: Ceftriaxone  Drug: Azithromycin tablets  Drug: IV levofloxacin  Drug: Levofloxacin tablets	Phase IV

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

• Patient must be 18 years or older.
• Patient must be hospitalized and require intravenous therapy for treatment of pneumonia
• Patient must have pneumonia as documented by relevant signs and symptoms and a positive chest X-ray.
• Patients cannot have certain underlying diseases or conditions as defined in the study protocol.

Alabama
      Pfizer Investigational Site, Phenix City,  Alabama,  36867,  United States
California
      Pfizer Investigational Site, Sylmar,  California,  91342,  United States
      Pfizer Investigational Site, Long Beach,  California,  90822,  United States
Florida
      Pfizer Investigational Site, Sarasota,  Florida,  34239,  United States
Georgia
      Pfizer Investigational Site, Ft. Gordon,  Georgia,  30905,  United States
      Pfizer Investigational Site, Columbus,  Georgia,  31904,  United States
Kansas
      Pfizer Investigational Site, Shawnee Mission,  Kansas,  66204,  United States
Kentucky
      Pfizer Investigational Site, Louisville,  Kentucky,  40202,  United States
Michigan
      Pfizer Investigational Site, Detroit,  Michigan,  48202,  United States
      Pfizer Investigational Site, Royal Oak,  Michigan,  48073,  United States
Missouri
      Pfizer Investigational Site, Kirkwood,  Missouri,  63122,  United States
      Pfizer Investigational Site, Saint Louis,  Missouri,  63110,  United States
New Mexico
      Pfizer Investigational Site, Albuquerque,  New Mexico,  87108,  United States
New York
      Pfizer Investigational Site, New York,  New York,  10003,  United States
      Pfizer Investigational Site, Mineola,  New York,  11501,  United States
North Carolina
      Pfizer Investigational Site, Winston Salem,  North Carolina,  27103,  United States
Ohio
      Pfizer Investigational Site, Cleveland,  Ohio,  44106,  United States
Pennsylvania
      Pfizer Investigational Site, Sellersville,  Pennsylvania,  18960,  United States
      Pfizer Investigational Site, Philadelphia,  Pennsylvania,  19140,  United States
Texas
      Pfizer Investigational Site, San Antonio,  Texas,  78229,  United States
Canada, Manitoba
      Pfizer Investigational Site, Winnipeg,  Manitoba,  R3A 1R9,  Canada
Canada, Nova Scotia
      Pfizer Investigational Site, Halifax,  Nova Scotia,  B3H 3A7,  Canada
Canada, Ontario
      Pfizer Investigational Site, Hamilton,  Ontario,  L8V 1C3,  Canada
      Pfizer Investigational Site, London,  Ontario,  N6A 4G5,  Canada
      Pfizer Investigational Site, Ottawa,  Ontario,  K1Y 4E9,  Canada
Canada, Quebec
      Pfizer Investigational Site, Saint-Nicolas,  Quebec,  G7A 2S2,  Canada
      Pfizer Investigational Site, Montreal,  Quebec,  H1T 2M4,  Canada
Canada, Saskatchewan
      Pfizer Investigational Site, Regina,  Saskatchewan,  S4P 127,  Canada
      Pfizer Investigational Site, Saskatoon,  Saskatchewan,  S7L 2W1,  Canada
Germany
      Pfizer Investigational Site, Berlin,  D-14109,  Germany
      Pfizer Investigational Site, LUEDENSCHEID,  58515,  Germany
Germany, Niedersachen
      Pfizer Investigational Site, ROTENBURG,  Niedersachen,  D-27356,  Germany
Greece
      Pfizer Investigational Site, Athens,  15126,  Greece
Spain
      Pfizer Investigational Site, Barcelona,  08036,  Spain
Spain, CATALUNA
      Pfizer Investigational Site, Tarrasa,  CATALUNA,  08221,  Spain

Study ID Numbers:  A0661035
Record last reviewed:  November 2002
Last Updated:  October 13, 2004
Record first received:  May 2, 2002
ClinicalTrials.gov Identifier:  NCT00035347
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08